Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Health Canada approves LYNPARZA™ for the Treatment of Ovarian Cancer in Patients with BRCA-Mutations Français


News provided by

AstraZeneca Canada Inc.

May 03, 2016, 07:59 ET

Share this article

Share toX

Share this article

Share toX

First PARP inhibitor offers new treatment approach for the most fatal of women's cancers

MISSISSAUGA, ON, May 3, 2016 /CNW/ - AstraZeneca Canada announced today that Health Canada has approved LYNPARZA™ (olaparib) capsules as a maintenance treatment for patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer. LYNPARZA is the first poly ADP-ribose polymerase (PARP) inhibitor available in Canada, and has been granted the Health Canada Notice of Compliance with Conditions (NOC/c), based on promising evidence of clinical efficacy and duration of response data.1

"Health Canada's approval of LYNPARZA is particularly significant for patients with advanced BRCA-mutated ovarian cancer. Until now, there have been very limited options available to this unique segment of women living with this disease," says Dr. Michael Fung Kee Fung, Head, Division of Surgical Oncology, Ottawa Regional Cancer Centre and Professor, Division of Obstetrics & Gynecology and Department of Surgery, University of Ottawa. "The availability of this targeted treatment which works in the presence of BRCA mutations represents a successful application of our growing understanding of this disease. It gives us another way to battle this devastating disease, with fewer side effects compared to existing chemotherapies, which can often be debilitating for patients."

The Effect of Genes on Ovarian Cancer

Ovarian cancer is the most fatal women's cancer – every day, five Canadian women will die from this disease.2 Difficult to detect and often misdiagnosed, the disease is often caught in its late stages, meaning that 55 per cent of women diagnosed will die within five years.3

A quarter of all ovarian cancer cases are due to hereditary syndromes – up to 60 per cent of women with a BRCA mutation will be diagnosed with ovarian cancer.4 A BRCA mutation can be inherited from either parent and women with a BRCA mutation are more likely to be diagnosed with ovarian cancer at a younger age than those without a genetic mutation.5 This genetic marker indicates an increased risk, but also now offers the possibility of a targeted treatment option for women already diagnosed with ovarian cancer.6

"Outcomes for women living with ovarian cancer haven't significantly improved in over 50 years, the only way to change this is through improved treatments and further research. As more information about the role of genetics in ovarian cancer becomes available, targeted treatments such as LYNPARZA offer new hope for a personalized approach that better treats this disease," says Elisabeth Baugh, CEO, Ovarian Cancer Canada. "It's imperative that women who are diagnosed with ovarian cancer learn about their BRCA status so they can benefit from a treatment regime that is more specific to their particular case."

About PARP inhibitors

PARP inhibitors are a new class of targeted cancer therapy that function by disabling the ability of BRCA-mutated tumour cells to repair their damaged DNA. This kills tumour cells, with little or no effect on normal cells.7 LYNPARZA's approval represents a significant milestone as the first biomarker-driven targeted treatment for BRCA-mutated ovarian cancer, and this innovative and first-of-its-kind treatment has the ability to actively extend progression-free survival.8

Patients with relapsed BRCA-mutated ovarian cancer have an incurable and ultimately fatal disease with the prospect of multiple, repeated regimens of cytotoxic chemotherapy with associated cumulative toxicities.9 LYNPARZA is generally safe and tolerable, making it suitable as a maintenance therapy, and delays progression and the need for subsequent chemotherapy, offering patients more time before requiring the next chemotherapy.10,11,12

Regulatory approval is based on efficacy and safety data from a randomized, double-blind, placebo-controlled Phase II study. Efficacy of LYNPARZA is based on an analysis conducted of 136 women with BRCA-mutated advanced ovarian cancer treated with two or more prior lines of chemotherapy. Patients with BRCA-mutated ovarian cancer received the greatest treatment benefit from LYNPARZA, which significantly prolonged median progression-free survival compared with a placebo (11.2 months vs. 4.3 months). Studies have identified most common adverse reactions including mild to moderate nausea, vomiting, fatigue and anaemia.10,11,12

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 675 employees across the country and our AstraZeneca Canada headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.

REFERENCES:

1Kaufman B, Shapira-Frommer R, Schmultzler RK et al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. Journal of Clinical Oncology 2014. Accessed April 11, 2016. Available at:  http://jco.ascopubs.org/content/early/2014/10/30/JCO.2014.56.2728 
2Canadian Cancer Society, Statistics Canada, Public Health Agency of Canada, Provincial/Territorial Cancer Registries. Canadian Cancer Statistics 2015. Page 46, Accessed April 11, 2016. Available at: http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on 
3Ovarian Cancer Canada. Ovarian Cancer Fact Sheet. Accessed April 11, 2016. Available at: http://ovariancanada.org/OCC/media/Content/PDFs/Brochures/Ovarian-Cancer-FactSheet-EN.pdf 
4Canadian Cancer Society, BRCA gene mutations. Accessed April 11, 2016. Available at:  http://www.cancer.ca/en/cancer-information/cancer-101/what-is-a-risk-factor/genetic-risk/brca-gene-mutations/?region=on 
5Litton, J.K. et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012 Jan 15;118(2):321-5.
6Canadian Cancer Society, BRCA gene mutations. Accessed April 11, 2016. Available at:  http://www.cancer.ca/en/cancer-information/cancer-101/what-is-a-risk-factor/genetic-risk/brca-gene-mutations/?region=on 
7Chen, A, PARP inhibitors: its role in treatment of cancer, Chin J Cancer. 2011 Jul; 30(7): 463–471. Accessed April 11, 2016. Available at: http://www.cjcsysu.com/abstract.asp?idno=17747 
8LYNPARZA™ (olaparib) Product Monograph, on file.
9McWhinney,S, Goldberg, R and McLeod, H,  Platinum Neurotoxicity Pharmacogenetics, Molecular Cancer Therapeutics, January 2009 8; 10.  Accessed April 11, 2016. Available at: http://mct.aacrjournals.org/content/8/1/10.long 
10LYNPARZA™ (olaparib) Product Monograph, on file.
11Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852-61.
12Matulonis U, Oza A, Ho T, Ledermann J et al. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer. 2015 Jun 1;121(11):1737-46.

SOURCE AstraZeneca Canada Inc.

Lisa Cancian, Weber Shandwick, Tel: 416-642-7945, E-mail: [email protected]; Daniela Cohen, AstraZeneca Canada, Tel: 905-615-6827, E-mail: [email protected]

Modal title

Organization Profile

AstraZeneca Canada Inc.

    Also from this source

  • ENHERTU® (trastuzumab deruxtecan) Receives Time-Limited Reimbursement Recommendation from Canada's Drug Agency for Gastric Cancer

  • Tagrisso® approved (with conditions) in Canada for patients with unresectable, Stage III EGFR-mutated non-small cell lung cancer (NSCLC)

  • /C O R R E C T I O N from Source -- AstraZeneca Canada Inc., Plan International Canada, Eureka Fellowship/

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.